Madison Investment Holdings Inc. Boosts Stake in Becton, Dickinson and Company (BDX)

Madison Investment Holdings Inc. lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 1.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,931 shares of the medical instruments supplier’s stock after purchasing an additional 506 shares during the quarter. Madison Investment Holdings Inc.’s holdings in Becton, Dickinson and were worth $5,865,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of BDX. Koch Industries Inc. raised its position in Becton, Dickinson and by 45,268.7% during the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after purchasing an additional 1,395,182 shares during the last quarter. Vanguard Group Inc. raised its position in Becton, Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares during the last quarter. Winslow Capital Management LLC bought a new position in Becton, Dickinson and during the 2nd quarter valued at approximately $225,164,000. Janus Henderson Group PLC raised its position in Becton, Dickinson and by 1,265.9% during the 2nd quarter. Janus Henderson Group PLC now owns 1,210,837 shares of the medical instruments supplier’s stock valued at $236,245,000 after purchasing an additional 1,122,191 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in Becton, Dickinson and by 216.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 1,320,259 shares of the medical instruments supplier’s stock valued at $257,596,000 after purchasing an additional 902,761 shares during the last quarter. Hedge funds and other institutional investors own 88.60% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at $218.31 on Tuesday. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03. The firm has a market capitalization of $50,082.27, a P/E ratio of 23.15, a P/E/G ratio of 1.72 and a beta of 1.07. Becton, Dickinson and Company has a 52 week low of $161.50 and a 52 week high of $229.68.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.12 EPS. analysts forecast that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be paid a $0.75 dividend. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $3.00 annualized dividend and a dividend yield of 1.37%. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. Becton, Dickinson and’s dividend payout ratio is presently 64.52%.

BDX has been the subject of a number of recent analyst reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Zacks Investment Research lowered Becton, Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. Royal Bank of Canada reissued a “hold” rating and issued a $210.00 target price on shares of Becton, Dickinson and in a research report on Wednesday, October 25th. Morgan Stanley increased their target price on Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $217.08.

TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/12/madison-investment-holdings-inc-boosts-stake-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply